Gefitinib Eugia (Uk)

Gefitinib Eugia (Uk) is an oral medication used to treat certain types of cancer. This pharmaceutical is manufactured by Eugia (Uk) Ltd and is designed for targeted therapy.

Gefitinib Eugia (Uk) is primarily used in the treatment of specific types of cancer, particularly non-small cell lung cancer. It works by targeting certain proteins that help cancer cells grow and divide. This medication is often prescribed for patients who have specific genetic mutations that make them suitable candidates for this type of therapy.

Common effects of Gefitinib Eugia (Uk) may include skin rash, diarrhea, and nausea. Some users might also experience dry skin, loss of appetite, and fatigue. These effects can vary in intensity and duration depending on the individual.

Gefitinib Eugia (Uk) should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. This medication may not be suitable for everyone, especially those with certain medical conditions or allergies.

Gefitinib Eugia (Uk) can interact with other medications, including certain antibiotics, antifungals, and seizure medications. It is important to inform your healthcare provider about all the medications you are taking to avoid potential interactions. Additionally, consuming grapefruit or grapefruit juice while taking this medication should be avoided.